HUIZHOU, China, June 12, 2025 /PRNewswire/ -- Desay Battery, a global leader in energy storage innovations, achieved a key milestone at the 2025 SNEC PV+ Expo, by announcing a strategic partnership with Demir Enerji, Turkey's leading energy company. Both parties are committed to collaborating on several energy storage projects in Ukraine, including the MHP Chicken Block Solar + ESS 2.5MW/5MWh project, MHP Project #1 with a capacity of 2MW/5MWh and Project #2 with 20MW/40MWh, as well as the VOLTAGEG project with 10MW/40MWh.
"Through our partnership with Demir Enerji, we are excited to bring our most advanced energy storage technologies to Turkey's dynamic energy market," said Vice-President Jack Guo of Desay Battery. "This collaboration is a significant step in our global expansion strategy and highlights our dedication to advancing the transition to clean energy globally."
At the exhibition, Desay Battery showcased cutting-edge battery cell technology, featuring a diverse range of products. This lineup included high-performance lithium-ion cells (DLP-100, DLP-280, DLP-314) as well as the innovative DSP-60 sodium-ion battery. In addition to cell technology, Desay Battery unveiled its modular energy storage systems, which consist of scalable lithium modules at 100Ah and 280Ah, along with 52S battery packs that allow for flexible integration. For commercial and industrial applications, the company introduced the Lumos energy storage cabinets with capacities of 215kWh and 344kWh. For residential use, offerings included the 10-25kWh LV Residential ESS and the 21kWh HV DCDC Residential ESS (280Ah), designed to provide efficient and space-saving solutions for homes. Furthermore, Desay Battery exhibited large-scale infrastructure solutions, including the Vita 5MWh Utility ESS liquid-cooled container storage system, which supports grid stability, as well as UPS battery cabinets designed for critical backup power.
The products showcased not only highlight Desay Battery's leadership in energy storage technology but also demonstrate the company's deep understanding of diverse application needs, along with its ability to deliver precise, tailored solutions.
"With over 20 years of specialized experience, Desay Battery has firmly positioned itself as a Tier 1 energy storage provider, recently earning a spot on BloombergNEF's Energy Storage Tier 1 List for Q2 2025. This recognition underscores the company's vertically integrated approach, which covers the entire spectrum from cell development to complete system integration. Supported by state-of-the-art manufacturing facilities and rigorous quality control processes, Desay Battery continues to set the standard in the energy storage industry."
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Desay Battery Unveils Innovative Energy Storage Solutions at SNEC PV+ Expo, Announces Strategic Partnership with Turkish Energy Leader Demir Enerji
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
